Established Leader Brings Global SaaS and
Healthcare Technology Experience to Board
Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell” or the “Company”), a
leader in transforming the pharmacy care delivery model, today
announced it has increased its number of board seats from 9 to 10,
and has appointed Kaushik “Bobby” Ghoshal to fill the newest seat
as an independent director of Omnicell’s Board of Directors,
effective immediately.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230711576271/en/
Omnicell Appoints Bobby Ghoshal to Board
of Directors (Photo: Business Wire)
Mr. Ghoshal is an established technology leader who brings more
than 30 years of experience across multiple industries including
finance, semiconductors, and healthcare. In Mr. Ghoshal’s current
role as President of SaaS for ResMed, Inc. (“ResMed”), he leads the
Company’s global software business and is responsible for the
vision, strategy, and day-to-day operations of the Company’s
rapidly expanding SaaS portfolio. Prior to this, he served as
ResMed’s Chief Technology Officer. He has also served as Chief
Operating Officer of Brightree LLC, a ResMed-owned provider of
cloud-based SaaS for out-of-hospital care.
“We are delighted to welcome Bobby to Omnicell’s Board of
Directors,” said Randall Lipps, chairman, president, chief
executive officer, and founder of Omnicell. “Bobby has an
impressive track record leading high-performance teams in software
products, digital and business transformation, information
security, data analytics, and artificial intelligence and machine
learning. We look forward to benefitting from his unique
perspective at the intersection of SaaS and healthcare, as we
continue to work to transform the pharmacy care delivery model and
deliver value for our stakeholders, our healthcare partners, and
their patients.”
“Every day, customers rely on Omnicell to deliver
mission-critical medication management solutions and I am honored
to join the Company’s Board,” said Mr. Ghoshal. “I have been
impressed with Omnicell’s progress toward realizing the industry
vision of the Autonomous Pharmacy and am excited to have the
opportunity to take part in helping the Company achieve its goals.
I look forward to leveraging my background in SaaS and healthcare
to build on Omnicell’s strong foundation and help deliver on its
mission to improve patient outcomes.”
The addition of Mr. Ghoshal to Omnicell’s Board is part of the
Board’s ongoing refreshment process, which has resulted in the
addition of five new directors in the last four years. In
connection with his appointment, Mr. Ghoshal will join the Board’s
Corporate Governance Committee. The Board now comprises 10
directors, 9 of whom are independent and all of whom bring a broad
range of skills and experience that enhance the Board’s ability to
effectively fulfill its governance and oversight
responsibilities.
About Omnicell
Since 1992, Omnicell has been committed to transforming the
pharmacy care delivery model in an effort to optimize financial and
clinical outcomes across all settings of care. Through a
comprehensive portfolio of automation and advanced services,
Omnicell is uniquely positioned to address evolving healthcare
challenges, connect settings of care, and streamline the medication
management process. Healthcare facilities worldwide partner with
Omnicell to help increase operational efficiency, reduce medication
errors, improve patient safety, and enhance patient engagement and
adherence, helping to reduce costly hospital readmissions. To learn
more, visit omnicell.com.
From time to time, Omnicell may use the Company’s investor
relations website and other online social media channels, including
its Twitter handle www.twitter.com/omnicell, LinkedIn page
www.linkedin.com/company/omnicell, and Facebook page
www.facebook.com/omnicellinc, to disclose material non-public
information and comply with its disclosure obligations under
Regulation Fair Disclosure (“Reg FD”).
OMNICELL and the Omnicell logo are registered trademarks of
Omnicell, Inc. or one of its subsidiaries.
Forward-Looking Statements
To the extent any statements contained in this press release
deal with information that is not historical, these statements are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Without limiting the
foregoing, statements including the words “expect,” “intend,”
“may,” “will,” “should,” “would,” “could,” “plan,” “potential,”
“anticipate,” “believe,” “forecast,” “guidance,” “outlook,”
“goals,” “target,” “estimate,” “seek,” “predict,” “project,” and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are subject to the
occurrence of many events outside Omnicell’s control. Such
statements include, but are not limited to, Omnicell’s expectations
regarding the director appointment and statements about Omnicell’s
strategy, plans, objectives, goals, vision, and expected benefits.
Actual results and other events may differ significantly from those
contemplated by forward-looking statements due to numerous factors
that involve substantial known and unknown risks and uncertainties.
These risks and uncertainties include, among other things, (i)
unfavorable general economic and market conditions, including the
impact and duration of inflationary pressures, (ii) Omnicell’s
ability to recruit and retain skilled and motivated personnel,
(iii) Omnicell’s ability to take advantage of growth opportunities
and develop and commercialize new solutions and enhance existing
solutions, (iv) risks related to Omnicell’s investments in new
business strategies or initiatives, including its transition to
selling more products and services on a subscription basis, and its
ability to acquire companies, businesses, or technologies and
successfully integrate such acquisitions, (v) risks related to
failing to maintain expected service levels when providing our
Advanced Services or retaining our Advanced Services customers,
(vi) Omnicell’s ability to meet the demands of, or maintain
relationships with, its institutional, retail, and specialty
pharmacy customers, (vii) continued and increased competition from
current and future competitors in the medication management
automation solutions market and the medication adherence solutions
market, and (viii) other risks and uncertainties further described
in the “Risk Factors” section of Omnicell’s most recent Annual
Report on Form 10-K, as well as in Omnicell’s other reports filed
with or furnished to the United States Securities and Exchange
Commission (“SEC”), available at www.sec.gov. Forward-looking
statements should be considered in light of these risks and
uncertainties. Investors and others are cautioned not to place
undue reliance on forward-looking statements. All forward-looking
statements contained in this press release speak only as of the
date of this press release. Omnicell assumes no obligation to
update any such statements publicly, or to update the reasons
actual results could differ materially from those expressed or
implied in any forward-looking statements, whether as a result of
changed circumstances, new information, future events, or
otherwise, except as required by law.
OMCL-E
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230711576271/en/
For more information, contact:
Kathleen Nemeth Senior Vice President, Investor Relations
Kathleen.Nemeth@omnicell.com 650-435-3318
Omnicell (NASDAQ:OMCL)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Omnicell (NASDAQ:OMCL)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024